Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Lexicon Pharmaceuticals, Inc.    LXRX

LEXICON PHARMACEUTICALS, INC. (LXRX)
Mes dernières consult.
Most popular
  Report  
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 86,5 M
EBIT 2017 -143 M
Net income 2017 -146 M
Finance 2017 34,0 M
Yield 2017 -
Sales 2018 123 M
EBIT 2018 -108 M
Net income 2018 -116 M
Debt 2018 138 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 9,29x
EV / Sales2018 7,96x
Capitalization 837 M
More Financials
Company
Lexicon Pharmaceuticals, Inc. operates as a biopharmaceutical company which focuses on the development of breakthrough treatments for human disease.It has multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications.The company was... 
More about the company
Surperformance© ratings of Lexicon Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on LEXICON PHARMACEUTICALS, I
02/16Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Financial R..
GL
01/02LEXICON PHARMACEUTICALS : Announces Poster Presentation at ASCO GI
PU
01/02Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
GL
2017LEXICON PHARMACEUTICALS : Secures Up To $200 Million Non-dilutive Term Loan Fina..
AQ
2017LEXICON PHARMACEUTICALS : Akin Gump Advises BioPharma Credit Investment Funds in..
AQ
2017LEXICON PHARMACEUTICALS, INC. (NASDA : LXRX) Files An 8-K Entry into a Material ..
AQ
2017Lexicon Pharmaceuticals Secures Up To $200 Million Non-Dilutive Term Loan Fin..
GL
2017Lexicon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Prov..
AQ
2017LEXICON PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
AQ
2017LEXICON PHARMACEUTICALS, INC. (NASDA : LXRX) Files An 8-K Results of Operations ..
AQ
More news
Sector news : Bio Therapeutic Drugs
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2015SEEKING ALPHA'S BIOTECH WEEKLY : A Gilead Victory, Celladon Crumbles, And More 
2015Lexicon Undervalued As It Approaches A Major Event 
2015Lexicon Pharmaceuticals' (LXRX) CEO Lonnel Coats on Q1 2015 Results - Earning.. 
2015Lexicon Pharmaceuticals EPS in-line, beats on revenue 
2015Lexicon Pharmaceuticals - A Diamond In The Rough? 
Chart LEXICON PHARMACEUTICALS, I
Duration : Period :
Lexicon Pharmaceuticals, I Technical Analysis Chart | LXRX | US5288721047 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 23,2 $
Spread / Average Target 192%
EPS Revisions
Managers
NameTitle
Lonnel Coats President, Chief Executive Officer & Director
Raymond Debbane Chairman
Jeffrey L. Wade CFO, EVP-Corporate & Administrative Affairs
Pablo Lapuerta Chief Medical Officer & EVP-Clinical Development
Frank P. Palantoni Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LEXICON PHARMACEUTICALS, INC.12.10%854
GILEAD SCIENCES14.21%106 851
VERTEX PHARMACEUTICALS4.94%39 772
REGENERON PHARMACEUTICALS-12.04%35 529
BIOVERATIV INC91.99%11 201
GENMAB4.28%11 055